Table 5.
Relationship between serum levels of mucin 2 and clinicopathological parameters in patients with colorectal cancer, n (%)
|
Clinicopathological parameter
|
n
(%)
|
Serum MUC2 expression
|
χ2
|
P
value
|
|
|
Low, n (%)
|
High, n (%)
|
||||
| Age, yr | |||||
| ≤ 60 | 30 | 11 (36.7) | 19 (63.3) | 0.080 | 0.777 |
| > 60 | 36 | 12 (33.3) | 24 (66.7) | ||
| Gender | |||||
| Male | 38 | 12 (31.6) | 26 (68.4) | 0.422 | 0.516 |
| Female | 28 | 11 (39.3) | 17 (60.7) | ||
| Tumor location | |||||
| Rectum and anus | 24 | 10 (47.1) | 14 (58.3) | 0.772 | 0.380 |
| Colon | 42 | 13 (31.0) | 29 (65.2) | ||
| TNM stage | |||||
| I-II | 36 | 16 (44.4) | 20 (55.6) | 6.687 | 0.033 |
| III | 21 | 7 (33.3) | 14 (66.7) | ||
| IV | 9 | 0 (0.0) | 9 (100.0) | ||
| Maximum tumor diameter | |||||
| < 5 cm | 33 | 12 (36.4) | 21 (63.6) | 0.067 | 0.796 |
| ≥ 5 cm | 33 | 11 (33.3) | 22 (66.7) | ||
| Depth of invasion | |||||
| Non-immersed serosa | 12 | 5 (41.7) | 7 (58.3) | 0.300 | 0.584 |
| Immersed serosa | 54 | 18 (33.3) | 36 (66.7) | ||
| Degree of differentiation | |||||
| High-moderate | 60 | 21 (38.3) | 39 (61.7) | F1 | 1.000 |
| Low | 6 | 2 (33.3) | 4 (66.7) | ||
| Tumor type | |||||
| Mucinous adenocarcinoma | 14 | 8 (57.1) | 6 (42.9) | 21.241 | < 0.01 |
| Non-mucinous adenocarcinoma | 52 | 15 (32.7) | 37 (67.3) | ||
| Lymph node metastasis | |||||
| No | 36 | 16 (44.4) | 20 (55.6) | 3.212 | 0.073 |
| Yes | 30 | 7 (23.3) | 23 (76.7) | ||
| Distant metastasis | |||||
| No | 57 | 23 (40.4) | 34 (59.6) | F1 | 0.022 |
| Yes | 9 | 0 (0.0) | 9 (100.0) | ||
1
Fisher exact test was used when the expected frequency was less than 1. Due to the small number of patients with stage I, in order to reduce bias, we combined the stage I with stage II patients for analysis. Similarly, there was only one patients with highly differentiated colorectal cancer, so this patient was combined with the patients with moderately differentiated disease. Serum levels of mucin 2 was correlated with tumor-node-metastasis stage, tumor type, and distant metastasis in colorectal cancer patients. MUC2: Mucin 2; TNM: Tumor-node-metastasis.